ABC Scores (Age, Biomarkers, Clinical history) stroke and bleeding scores are personalized stroke and bleeding risk assessment scores that incorporate clinical variables and cardiovascular biomarkers Elecsys® GDF-15, Elecsys® NT-proBNP, Elecsys® cTnT-hs and hemoglobin to estimate risk of stroke/systemic embolic events and bleeding in patients with atrial fibrillation. All of those biomarkers have been CE marked for use in ABC Scores.
ABC Scores have better prognostic performance vs. standard of care (CHA2DS2-VASc and HAS-BLED) as they have better discriminative ability and net reclassification benefit validated and calibrated in over 37’000 patients from six major pharmaceutical trials. This is expressed by improved C-statistics of ABC Scores vs. standard of care risk tools like CHA2DS2-VASc and HAS-BLED1-5.
Patient outcomes (clinical utility) and economic utility data for ABC Scores is currently in generation with the prospective, interventional, randomized clinical trial called ‘ABC-AF’6. Possible outcomes of this trial could indicate improvements in overall patient management and cost effectiveness. The results will be published in 2026.
About ABC1000 Program
ABC1000 is a commercial product evaluation program offered to physicians who diagnose and treat patients with atrial fibrillation and would like to try the novel ABC stroke and ABC bleeding scores to risk stratify them. Roche Diagnostics aims to touch the lives of approximately 1000 atrial fibrillation patients with this initiative.
Within the framework of the ABC1000 Program, the physicians and their institutions will benefit from getting access to innovative risk assessment tools, including a new biomarker GDF-15. The physicians are asked to try out the ABC Scores in their daily practice and assess their experience and satisfaction with them. ABC Scores can be used along the current standard of care methods and are not supposed to replace them for the duration of the Program.
This product evaluation program is applicable only in countries where Elecsys® GDF‑15, Elecsys® NT‑proBNP and Elecsys® cTnT‑hs have regulatory approval..